Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
12.11. | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
08.11. | iSpecimen Inc.: iSpecimen Named Top Competitor in $4.4 Billion USD Market | 231 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - November 8, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens... ► Artikel lesen | |
07.11. | iSpecimen Inc: iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually | 2 | GlobeNewswire (USA) | ||
07.11. | iSpecimen Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
31.10. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
31.10. | iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
ISPECIMEN Aktie jetzt für 0€ handeln | |||||
30.10. | iSpecimen sets $5 million public stock offering at $3 per share | 2 | Investing.com | ||
30.10. | iSpecimen setzt öffentliches Aktienangebot von 5 Millionen US-Dollar zu 3 US-Dollar pro Aktie fest | 2 | Investing.com Deutsch | ||
30.10. | iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
18.10. | iSpecimen files to sell 1.2M shares of common stock | 2 | Seeking Alpha | ||
18.10. | iSpecimen Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
02.10. | iSpecimen Regains Nasdaq compliance, faces arbitration claim | 1 | Investing.com | ||
26.09. | iSpecimen secures $1 million loan, revamps board | 1 | Investing.com | ||
26.09. | iSpecimen sichert sich Darlehen über 1 Million US-Dollar und strukturiert Vorstand um | 5 | Investing.com Deutsch | ||
26.09. | iSpecimen Inc: iSpecimen Secures $1 Million Loan; Appoints Three New Board Members | 1 | GlobeNewswire (USA) | ||
25.09. | iSpecimen Inc. - 8-K, Current Report | 2 | SEC Filings | ||
12.09. | ISpecimen Down 19% In Pre-market Following Reverse Stock Split | 2 | RTTNews | ||
11.09. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.09. | iSpecimen announces 1-for-20 reverse stock split | 1 | Seeking Alpha | ||
11.09. | iSpecimen Inc: iSpecimen Announces 1-for-20 Reverse Stock Split | 128 | GlobeNewswire (Europe) | WOBURN, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EPIGENOMICS | 1,200 | +20,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
ILLUMINA | 135,20 | +0,48 % | Illumina-Aktie kaum gefragt: Kurs bricht um 3,47 Prozent ein (123,0856 €) | Die Aktie von Illumina zählt heute zu den großen Verlierern an der Börse. Das Papier verliert deutlich an Wert. Kein guter Tag bislang für Inhaber von Illumina: Die Aktie weist derzeit einen Kursrückgang... ► Artikel lesen | |
CRISPR THERAPEUTICS | 46,000 | +4,07 % | Why Is CRISPR Therapeutics AG (CRSP) Among the Worst Performing Biotech Stocks in 2024? | ||
INTELLIA THERAPEUTICS | 13,715 | -0,11 % | Gen-Schere Hoffnungsträger Intellia Therapeutics: Aktie mit Kurssprung - die Hintergründe | Das Gros der Biotech- und Pharmawerte hat in den vergangenen Tagen nach der Ankündigung Donald Trumps, Robert F. Kennedy Jr. als Gesundheitsminister für die künftige Regierung nominieren zu wollen,... ► Artikel lesen | |
EDITAS MEDICINE | 2,405 | +2,87 % | Editas Medicine, Inc.: Editas Medicine Announces Third Quarter 2024 Results and Business Updates | Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine's proprietary targeted LNP in a key step to developing a novel... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,361 | -1,63 % | Defence Therapeutics Inc.: Defence Announces Closing of Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
NEUROCRINE BIOSCIENCES | 119,85 | -0,66 % | Neurocrine Biosciences Aktie: Positive Überraschung erwartet! | ||
BLUEBIRD BIO | 0,340 | +1,83 % | bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance | SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September... ► Artikel lesen | |
GALAPAGOS NV | 25,860 | -0,39 % | GALAPAGOS NV - S-8, Securities to be offered to employees in employee benefit plans | ||
ARROWHEAD PHARMACEUTICALS | 17,805 | +0,08 % | Arrowhead Pharmaceuticals submits plozasiran NDA to treat FCS | ||
GINKGO BIOWORKS | 6,900 | 0,00 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
CARDIFF ONCOLOGY | 2,370 | +0,42 % | Cardiff Oncology secures patent for cancer drug combo | ||
TWIST BIOSCIENCE | 39,870 | -1,60 % | Cathie Wood's ARK makes major plays in Recursion, Twist Bioscience stock | ||
REPLIGEN | 136,30 | -0,47 % | Repligen-Direktor Hunt verkauft Aktien im Wert von 3,39 Millionen US-Dollar | ||
RECURSION PHARMACEUTICALS | 5,695 | -0,96 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen |